Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

1904 - Sidedness of the Primary Tumor on the Effect of TAS-102 for Refractory metastatic colorectal cancer

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Presenters

Shinya Ueda

Citation

Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281

Authors

S. Ueda1, Y. Tsuboguchi2, Y. Nakatani3, A. Tsuya4, S. Nishina5, K. Akiyoshi2, S. Okazaki6, S. Tokunaga7, H. Daga2

Author affiliations

  • 1 Medical Oncology, Osaka City General Hospital, 630-0293 - Nara/JP
  • 2 Medical Oncology, Osaka City General Hospital, 534-0021 - Osaka/JP
  • 3 Medical Oncology, Osaka City General Hospital, 5340021 - Osaka/JP
  • 4 Clinical Oncology, Osaka City General Hospital, 534-0021 - Osaka/JP
  • 5 Medical Oncology, Ako central hospital, 678-0241 - Ako-city/JP
  • 6 Medical Oncology, Kyoto Medical Center, 612-0861 - Kyoto/JP
  • 7 Medical Oncology, Osaka City General Hospital, Osaka/JP
More

Resources

Abstract 1904

Background

TAS-102 study was shown to have clinical activity in a large population of Japanese and Western patientswith heavily pretreated metastatic colorectal cancer, including those whose disease was refractory to fluorouracil.But we know few date of TAS-102 in daily medical practice. So we assessed efficacy and safety of TAS-102 for refractory metastatic colorectal cancer.

Methods

We retrospectively reviewed the data of 86 patientswho received TAS-102 treatment in our institution between June2014 and October2017.TAS-102 (with each dose consisting of 35 mg per square meter) was administered twice daily, 5 days on and 2 days off for 2 weeks, followed by 2 weeksrest period. The regimen was repeated every 4 weeks.

Results

The median age was 69 years (range, 27–87). Performance status of 1 and 2 were 39 and 47 patients. RAS wild and mutant were 39 and 47 patients. Primary tumor site of right and left were 25 and 61 patients. All patients had received prior chemotherapy regimens containing a fluoropyrimidine, oxaliplatin, and irinotecan. 41 patients received 4 or more prior chemotherapy. Response rate and disease control rate of all were 1% and 24%. Right and left-sided of response rate were 4% and 0%. Right and left-sided of disease control rate were 32% and 19%. Median PFS was 62 days, right and left-sided were 55 and 64 days. Median OS was 216 days, right and left-sided were 262 and 200 days. OS was longer than previously reported. 40 patientsreceived subsequent chemotherapy. Adverse events were mild with 18% of Grade 4 neutropenia and 4% of Grade 3 febrile neutropenia.

Conclusions

TAS-102 was active and tolerable for heavily treated refractory metastatic colorectal cancer. There were no significant difference of PFS and OS in primary tumor site.

Clinical trial identification

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Editorial Acknowledgement

This publication is not Acknowledgement.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings